www.TinnitusTreatmentReport.com
https://www.globenewswire.com/news-release/2020/07/06/2058156/0/en/Otonomy-Reports-Positive-Top-Line-Results-from-Phase-1-2-Clinical-Trial-of-OTO-313-in-Patients-with-Tinnitus.html
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
https://clinicaltrials.gov/ct2/show/NCT03918109?type=Intr&cond=Tinnitus&phase=012345&lupd_s=04%2F03%2F2019&lupd_d=14
Condition : Tinnitus, Subjective
Interventions : Drug: OTO-313; Drug: Placebo
Sponsor : Otonomy, Inc.
Recruiting
OTO-313 in Subjects With Subjective Tinnitus
NCT03918109
Wed, 17 Apr 2019 12:00:00 EDT
https://www.globenewswire.com/news-release/2020/06/15/2048357/0/en/Otonomy-Provides-Update-on-Clinical-Trials-and-Development-Programs.html
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 16:05 ET | Source: Otonomy, Inc.
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and the timeline to results for the company’s three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménière’s disease. The company will host a conference call and webcast today at 4:30 p.m. ET to review these updates.
https://clinicaltrials.gov/ct2/show/NCT03918109?type=Intr&cond=Tinnitus&phase=012345&lupd_s=04%2F03%2F2019&lupd_d=14
https://www.globenewswire.com/news-release/2019/04/11/1802608/0/en/Otonomy-Initiates-Phase-1-2-Clinical-Trial-of-OTO-313-in-Tinnitus.html
